In the BioHarmony Drug Report Database

"Preview" Icon

Samidorphan

Lybalvi (samidorphan) is a small molecule pharmaceutical. Samidorphan was first approved as Lybalvi on 2021-05-28. It is known to target delta-type opioid receptor, kappa-type opioid receptor, and mu-type opioid receptor. Lybalvi’s patents are valid until 2032-02-13 (FDA).

 

Trade Name

 

Lybalvi
 

Common Name

 

samidorphan
 

ChEMBL ID

 

CHEMBL426084
 

Indication

 

 

Drug Class

 

Narcotic antagonists/agonists (morphinan derivatives)

Image (chem structure or protein)

Samidorphan structure rendering